SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 120 filers reported holding SYNAGEVA BIOPHARMA CORP in Q3 2014. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2015 | $48,003,000 | -6.1% | 492,190 | -10.6% | 0.04% | -7.1% |
Q4 2014 | $51,110,000 | +27.2% | 550,812 | -5.7% | 0.04% | +23.5% |
Q3 2014 | $40,196,000 | -29.5% | 584,409 | +7.4% | 0.03% | -29.2% |
Q2 2014 | $57,002,000 | +28.2% | 543,916 | +1.5% | 0.05% | +26.3% |
Q1 2014 | $44,465,000 | +99.8% | 535,911 | +55.8% | 0.04% | +90.0% |
Q4 2013 | $22,255,000 | -12.4% | 343,865 | -14.3% | 0.02% | -20.0% |
Q3 2013 | $25,411,000 | +36.9% | 401,373 | -9.2% | 0.02% | +25.0% |
Q2 2013 | $18,566,000 | – | 442,058 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Baker Brothers Advisors | 9,223,182 | $387,189,000 | 7.66% |
EMERALD MUTUAL FUND ADVISERS TRUST | 78,486 | $3,295,000 | 0.56% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,485,288 | $104,382,000 | 0.46% |
HARVEY CAPITAL MANAGEMENT INC | 34,800 | $1,460,000 | 0.45% |
EMERALD ADVISERS, LLC | 148,232 | $6,223,000 | 0.38% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 148,411 | $6,233,000 | 0.27% |
ArrowMark Colorado Holdings LLC | 15,500 | $651,000 | 0.18% |
CR Intrinsic Investors, LLC | 118,161 | $4,963,000 | 0.17% |
BB BIOTECH AG | 53,549 | $2,248,000 | 0.16% |
TURNER INVESTMENTS LLC | 209,744 | $8,806,000 | 0.12% |